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Poster Session II 131recipient respectively. Cumulative incidence of grade II-IV
aGVHD in IG and CG was 25% and 35% respectively (p .
0.05). No difference was seen in days to onset of aGVHD between
the two groups. Patient age, sex, donor type and conditioning reg-
imen had no effect on the probability of response to infliximab.
Rates of chronic GVHD in IG and CG were 84% and 61% respec-
tively (p5 0.22). Pts in IG had significantly more fungal infections
(n5 5) compared to CG (n5 1) (p5 0.02). Kaplan-Meier estimates
of 3 yr overall survival for IG and CG were 31% and 38% respec-
tively (p 5 0.42). Estimates of 3 yr progression free survival are
59% and 56% in similar order (p 5 0.68). Conclusion: In conclu-
sion, infliximab does not reduce incidence of grade II-IV aGVHD
compared to historic controls. It causes a significant increase in fun-
gal infections and may increase the likelihood of chronic GVHD.357
GRAFT-VERSUS-HOST DISEASE: A MINOR-MISMATCHEDMOUSE MODEL
WITH GRADUAL PROGRESSION FROM THE ACUTE INTO THE CHRONIC
PHASE
Mueller, A.M.S.1,2, Allen, J.A.1, Miklos, D.1, Shizuru, J.A.1. 1Stanford
School of Medicine, Stanford, CA; 2University Medical Center, Freiburg
i.Br., Germany.
Chronic graft-versus-host disease (cGVHD) is the most frequent
long-term complication after allogeneic hematopoietic cell trans-
plantation (HCT). While acute GVHD (aGVHD) is largely donor
T cell (TC) induced, the pathophysiology of cGVHD remains un-
clear. Amongst the issues to be clarified are the identification of the
TC subsets that drive the pathophysiology, the delineation of anti-
gen targets and the role of B cells (BC). Most experimental models
study acute GVHD, whereas models for the chronic phase are
scarce. C57BL/6 (B6)/BALB. B (H2Db) is an established mi-
nor-mismatched mouse model for aGVHD. Here, we assessed
whether mice also develop chronic long-term symptoms. Lethally
irradiated recipients were given FACS purified hematopoietic
stem cells (HSC: cKit1Thy1.1loLin-Sca11). For induction of
GVHD titrated doses of splenocytes (SP; 5  105–1  107) or pu-
rified CD4 or CD8 TC were co-transferred. Mice were followed
over an extended time (1 y) for clinical signs, weight loss, histology,
chimerism, and IgG synthesis (donor/host). Recipients of pure
HSC remained healthy, steadily increasing in weight (107% of
baseline (BL); d100). Mice given SP developed aGVHD with mor-
bidity and mortality correlating to the SP dose. Survivors of the
acute phase stabilized by d50–70, with only subtle signs for months,
andweight remained belowBL (d100: 93%/83% for 106/107 SP, re-
spectively). Ultimately, they developed a full-blown picture of
cGVHD, with erythrosquamous skin lesions, alopecia, cirrhotic
liver changes, and conjunctivitis at 1 y post-HCT. The most re-
markable histological changes were inflammatory periportal liver
infiltrates, which gradually progressed to fibrosis and complete dis-
ruption of a regular cell pattern. Intestines were primarily affected
in the acute phase, whereas skin changes (subcutaneous atrophy, in-
filtration of hair follicles) manifested late. CD4, but not CD8 TC
induced the full picture of aGVHD. Recipients of HSC remained
mixed chimeras, addition of SP promptly converted recipients to
full donor chimeras. Delays in BC reconstitution correlated with
the degree of aGVHD. Despite this, high levels of donor IgG syn-
thesis were observed. In conclusion, B6/ BALB. B is a valuable
model to study cGVHDwith convincing histological signs evolving
from acute changes. Mouse studies delineating the GVHD-induc-
ing TC subsets will improve our understanding of the pathophysi-
ology of GVHD, and will be an essential piece paving the way of
graft engineering.358
THE PTPN22 1858C/T POLYMORPHISM IS ASSOCIATED WITH THE DE-
VELOPMENT OF GRADE 3 TO 4 ACUTE GRAFT-VERSUS-HOST DISEASE
AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOL-
LOWING NONMYELOABLATIVE CONDITIONING
Kornblit, B.1,2, Masmas, T.1, Petersen, S.L.1, Madsen, H.O.2,
Garred, P.2, Vindelov, L.1. 1Rigshospitalet, University of Copenhagen,Copenhagen, Denmark; 2Rigshospitalet, University of Copenhagen, Co-
penhagen, Denmark.
Graft-versus-host disease (GVHD) is a cause of considerable
morbidity and mortality after allogeneic hematopoietic cell trans-
plantation (HCT) following nonmyeloablative conditioning. Ge-
netic polymorphisms in various genes, associated with the
immune system have been implicated in the development of
GVHD. The PTPN22 gene encodes LYP, which is involved in sup-
pression of T-cell receptor signalling. The 1858 C/T polymor-
phism in PTPN22, renders T-cells hyperresponsive, and the 1858
T allele has been implicated in conferring increased susceptibility
to various autoimmune diseases. As in autoimmunity, T-cell activa-
tion plays a key role in the development of GVHD. To asses the in-
fluence of the PTPN22 1858 C/T polymorphism on development
of GVHD after allogeneic HCT following nonmyeloablative con-
ditioning, 100 consecutive patient-donor pairs receiving allogeneic
HCT with related (n5 66) or unrelated (n5 34) donors for hema-
tological malignancies (HD 5 13, MM 5 14, CLL 5 12, NHL 5
17, MDS 5 18, AML 5 24, CML 5 2), between March 2000 and
December 2005 at Rigshospitalet, Denmark, were genotyped.
The cumulative incidence of grade 2–4 acute GVHD, grade 3–4
acute GVHD and extensive chronic GVHD was 67%, 24%, and
49%, with no difference between patients carrying the C/C or C/
T and T/T genotype or donors carrying the C/C or C/T and T/
T genotype. To assess a possible gene-dosage effect, the number
of T-alleles in each recipient-donor pair was cumulated, and the cu-
mulative incidence of grade 3–4 acute GVHD increased from 20%
in recipient-donor pairs carrying no or oneT-allele to 50% in recip-
ient-donor pairs carrying two or more T alleles (p 5 0.04), while
there was no difference in grade 2–4 acute and extensive chronic
GVHD between groups. In the competing risk regression analysis,
the recipient-donor pair genotype with 2 or more T-alleles was an
independent risk factor (hazard ratio 3.0; 95%CI 1.2–7.5) for devel-
opment of grade 3–4 acute GVHD, even after adjusting for baseline
variables known to affect GVHD rates. Furthermore, patients from
recipient-donor pairs carrying two or more T-alleles were hospital-
ized for more days (p 5 0.01) due to GVHD (median 5 15 days;
range 0–63 d), than patients from recipient-donor pairs with no
or one T-allele (median 5 0 days; range 0–104 d). Collectively,
our data suggest, that the PTPN22 1858 C/T polymorphism,
when present in both recipient and donor, is a risk factor for devel-
opment of grade 3–4 acute GVHD after nonmyeloablative condi-
tioning allogeneic HCT.359
IMMUNE ACTIVATION WITH INTERLEUKIN-2 AND GRANULOCYTE-
MACROPHAGE COLONY STIMULATING FACTOR FOR TREATMENT OF RE-
LAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Bachier, C.R., Shaughnessy, P., Smith, B., Salinas, R., LeMaistre, C.F.
Texas Transplant Institute, San Antonio, TX.
Donor lymphocyte infusion (DLI) is use for relapse after alloge-
neic stem cell transplant (ASCT). Immune activation with cytokines
maybe an alternative to DLI. We studied the use of Granulocyte-
Macrophage Colony Stimulating Factor (GM-CSF) and Interleu-
kin-2 (IL-2) for immune activation at the time of relapse after
ASCT in patients (pts) with hematologicmalignancies. Pts. received
subcutaneous GM-CSF at 500 mcg/day on days 1–14 and IL-2 at 1
 106 units/m2/day on days 8–14. Pts. were off immunosuppressive
therapy and had no prior history of graft versus host disease
(GVHD) at the start of treatment. Twelve pts. received IL-2/
GM-CSF for treatment of relapse AML (7), ALL (2), CML (1),
MDS (2). Median age was 55 (range 8–66). Stem cell sources in-
cluded: peripheral blood 5 9, bone marrow 5 2, umbilical cord
blood (UCB) 5 1. Donor sources were: match-related sibling 5 4
and match-unrelated donor5 8 (UCB5 1). Nine pts. had resistant
relapse or primary resistant disease at time of ASCT. Median time
from transplant to relapse was 4 months (range 5 1–14). Two pts.
had failed DLI and 5 pts. had received reinduction chemotherapy
prior to IL-2/GM-CSF. Eight pts. responded to IL-2/GM-CSF
(CR5 7, PR5 1). Two pts. remain disease free at 18 and 26months
post IL-2/GM-CSF. Six pts. developed GVHD and of these 4
were responders. Two pts. had GM-CSF discontinued due to in-
crease in peripheral blood blasts. No other toxicities related to
